Similar articles

• Live vaccine against measles, mumps, and rubella and the risk of hospital admissions for nontargeted infections.

  Sørup S, Benn CS, Poulsen A, Krause TG, Aaby P, Ravn H. Sørup S, et al. JAMA. 2014 Feb 26;311(8):826-35. doi: 10.1001/jama.2014.470. JAMA. 2014. PMID: 24570246
• Safety and immunogenicity of concurrent administration of live attenuated influenza vaccine with measles-mumps-rubella and varicella vaccines to infants 12 to 15 months of age.

  Nolan T, Bernstein DI, Block SL, Hilty M, Keyserling HL, Marchant C, Marshall H, Richmond P, Yogev R, Cordova J, Cho I, Mendelman PM; LAIV Study Group. Nolan T, et al. Pediatrics. 2008 Mar;121(3):508-16. doi: 10.1542/peds.2007-1064. Pediatrics. 2008. PMID: 18310199 Clinical Trial.
• Immunogenicity and safety of two tetravalent (measles, mumps, rubella, varicella) vaccines coadministered with hepatitis a and pneumococcal conjugate vaccines to children twelve to fourteen months of age.

  Blatter MM, Klein NP, Shepard JS, Leonardi M, Shapiro S, Schear M, Mufson MA, Martin JM, Varman M, Grogg S, London A, Cambron P, Douha M, Nicholson O, da Costa C, Innis BL. Blatter MM, et al. Pediatr Infect Dis J. 2012 Aug;31(8):e133-40. doi: 10.1097/INF.0b013e318259fc8a. Pediatr Infect Dis J. 2012. PMID: 22622699 Clinical Trial.
• When, and how, should we introduce a combination measles-mumps-rubella (MMR) vaccine into the national childhood expanded immunization programme in South Africa?

  Cameron NA. Cameron NA. Vaccine. 2012 Sep 7;30 Suppl 3:C58-60. doi: 10.1016/j.vaccine.2012.02.082. Vaccine. 2012. PMID: 22939023 Review.
• [Issues related to rubella, measles and epidemic parotiditis in the Russian Federation].

  Zverev VV, Iuminova NV. Zverev VV, et al. Vopr Virusol. 2004 May-Jun;49(3):8-11. Vopr Virusol. 2004. PMID: 15188648 Review. Russian.